Pier Francesco Ferrucci
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma(2015)8,054 cited
- → Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2017)5,337 cited
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial(2018)1,385 cited
- → The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells(1993)608 cited
- → Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma(2022)557 cited
- → Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab(2016)390 cited
- → Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial(2021)373 cited
- → Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma(2019)320 cited
- → Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma(2021)293 cited